PanTher Therapetics’ Sagittari platform brings a novel spin to traditional oncology drugs, helping deliver active ingredients to the tumor without affecting the bloodstream using methods inspired by cardiology interventions.
PanTher Therapeutics’ story began when CEO Laura Indolfi joined the Massachusetts Institute of Technology as a postdoctoral research associate to work on interventional approaches to localized disease treatment, with a focus on the cardiovascular space
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?